XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Ovarian Cancer Channel
subscribe to Ovarian Cancer newsletter

Latest Research : Cancer : Ovarian Cancer

   DISCUSS   |   EMAIL   |   PRINT
Latest blood testing technology for detecting epithelial ovarian cancer
Feb 23, 2006, 20:45, Reviewed by: Dr. Priya Saxena

"Ovarian cancer is one of the most difficult cancers to detect, especially in the earliest stages when it is more treatable,"

 
Yale University Office of Cooperative Research today announced that it has granted an exclusive license agreement with Laboratory Corporation of America Holdings (LabCorp) for the commercialization of the university's blood testing technology for epithelial ovarian cancer (EOC).

In the United States, EOC is the fourth most common cancer in women, and the leading cause of gynecologic cancer death. EOC affects approximately 25,000 women each year, and more than 16,000 will die from the disease.

The Yale technology for EOC is based on a collection of known serum proteins associated with cancer biology. Each protein marker is analyzed using a routine ELISA assay, and the results evaluated using a score system.

Research, led by Gil Mor, MD, associate professor of obstetrics, gynecology and reproductive sciences at Yale, was published on the technology in 2005. Statistical analyses on preliminary sample sets of a population of 206 women, including 24 patients with early stage (I/II) EOC and 76 with later stage (III/IV) EOC, showed a higher sensitivity and specificity than currently available tests, as well as a positive predictive value. Yale expects to conduct additional clinical studies on the test technology prior to its commercial introduction by LabCorp.

"Ovarian cancer is one of the most difficult cancers to detect, especially in the earliest stages when it is more treatable," said Myla P. Lai-Goldman, M.D., Executive Vice President, Chief Scientific Officer and Medical Director of LabCorp. "LabCorp continues to dedicate resources to identifying and commercializing tests to help discriminate earlier between disease-free and cancer patients."
 

- Research, led by Gil Mor, MD, associate professor of obstetrics, gynecology and reproductive sciences at Yale, was published on the technology in 2005.
 

http://www.yale.edu/

 
Subscribe to Ovarian Cancer Newsletter
E-mail Address:

 

More information about LabCorp is available online at http://www.LabCorp.com. The Yale University Office of Cooperative Research (YU-OCR) manages the intellectual assets created at Yale. Information on licensing agreements is available through or at http://www.yale.edu/ocr/ online

Citation: Proc Natl Acad Sciences, 102(21) May 24, 2005.


Related Ovarian Cancer News

Ovariectomy may put younger women at risk for an earlier death
Chronic stress agitates ovarian cancer
Acetaminophen may lower ovarian cancer risk
Ginger could help fight ovarian cancer
Multimarker assay for ovarian cancer most promising to date
Latest blood testing technology for detecting epithelial ovarian cancer
Intraperitoneal chemotherapy improves survival in ovarian cancer patients
Tea Drinking Reduces Risk of Ovarian Cancer
PKCi can be used as a potent predictive test in ovarian cancer
Ovarian Cancer: Can We Make the Clinical Diagnosis Earlier?


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us